Question 1

What is Swedish Orphan Biovitrum?

Accepted Answer

Swedish Orphan Biovitrum is a Company.

Question 2

How often does Swedish Orphan Biovitrum appear in global news?

Accepted Answer

Tracked across 4 news events drawn from 28 articles.

Question 3

When was Swedish Orphan Biovitrum first tracked by Ergen?

Accepted Answer

First tracked on Apr 09, 2026.

Question 4

When was Swedish Orphan Biovitrum last mentioned in news?

Accepted Answer

Last active on Aug 10, 2026.

Question 5

What is Swedish Orphan Biovitrum's current news sentiment?

Accepted Answer

Aggregate sentiment score: 34 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Swedish Orphan Biovitrum in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 4 events.

Question 7

What is the most recent event involving Swedish Orphan Biovitrum?

Accepted Answer

Sobi announces positive pozdeutinurad Phase 3 results (May 21, 2026, 6 articles).

Question 8

How did the "Sobi announces positive pozdeutinurad Phase 3 results" event impact Swedish Orphan Biovitrum?

Accepted Answer

Swedish Orphan Biovitrum announced positive topline results from its pivotal Phase 3 REDUCE 2 study for pozdeutinurad, which is expected to significantly enhance its presence in the gout treatment market and potentially boost its stock value.

Question 9

How did the "FDA issues CRL for Sobi's NASP" event impact Swedish Orphan Biovitrum?

Accepted Answer

Swedish Orphan Biovitrum received a Complete Response Letter from the FDA for its Biologics License Application for National Association of Securities Professionals, requiring additional data and addressing facility deficiencies. This delays the approval process for their drug.

Question 10

How did the "Sobi and Innate Pharma lacutamab partnership" event impact Swedish Orphan Biovitrum?

Accepted Answer

Sobi is the licensee and will pay $75 million upfront, gaining exclusive global commercialization rights to lacutamab. This strengthens its rare disease portfolio and provides growth potential.

Question 11

How did the "World Hemophilia Day 2026" event impact Swedish Orphan Biovitrum?

Accepted Answer

Swedish Orphan Biovitrum is a sponsor of World Hemophilia Day 2026, supporting the World Federation of Hemophilia's efforts.

Question 12

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.